全球高血压市场 – 行业趋势及 2030 年预测

高血压市场分析及规模

全球高血压药物市场增长的主要驱动因素是全球高血压突发事件的增加、糖尿病患者人数增加、技术进步和人口老龄化。此外，医疗支出增加、心血管疾病发病率增加和烟草使用者增加也推动了全球市场的增长。根据世界卫生组织 (WHO) 的数据，全球有超过 11.3 亿人患有高血压，其中每 5 人中只有 1 人治愈或得到控制。世卫组织还指出，在 21 世纪，高血压是隐形杀手之一，也是公共卫生的最大问题之一。

Data Bridge Market Research 分析称，高血压市场在 2022 年为 317.6 亿美元，预计到 2030 年将达到 431.8 亿美元，预计在 2023 年至 2030 年的预测期内复合年增长率为 4.00%。由于对药物的需求不断增长，“医院”在全球高血压市场的终端用户部分占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 整理的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。

高血压市场范围和细分

市场定义

高血压或血压升高会导致严重的疾病，从而显著增加患心脏、脑部和肾脏疾病的风险。血压由两个数字表示：收缩压，表示心脏收缩或跳动时血管内的压力；舒张压，表示心脏在两次跳动之间休息时血管内的压力。正常血压为 120/80 毫米汞柱。 

全球高血压市场动态

驱动程序

• 心血管疾病增加

据世界卫生组织统计，约有 60% - 85% 的人口过着久坐不动的生活。据美国疾病控制与预防中心统计，近 3100 万 50 岁以上的成年人过着久坐不动的生活，只有四分之一的美国成年人满足适当的身体活动需求。这促进了市场的增长。

• FDA 批准数量不断增加

持续的产品批准预计将促进市场增长。例如，2022 年 5 月，Zydus Lifesciences Limited 的子公司获得美国 FDA 的临时批准，销售用于治疗成人肺动脉高压(PAH) 的 Selexipag 片剂。2022 年 2 月，FDA 批准 Norliqva（氨氯地平）口服溶液用于治疗成人和 6 岁及以上儿童的高血压，以降低血压和冠状动脉疾病。

• 高血压患病率上升

根据美国心脏病学会的数据，尽管老年人的高血压发病率最高，心血管发病率和死亡率 (BP) 也最高，但老年人的高血压治疗大多不足。根据美国国家健康和营养检查调查 (NHANES) 的记录，高血压影响了 70% 的 65 岁以上人群。随着人口老龄化，这一数字将继续上升。随着对阻滞剂的需求增加，这将为市场增长创造更多机会。

机会

• 零售药店需求不断增长

The rise in the number of hypertension drugs delivered through retail pharmacies and the rise in the number of retail pharmacies in highly developed countries can create opportunities for market growth.  In addition, patients prefer retail pharmacies for purchasing drugs, as these are easily available such as increasing applications will create lucrative opportunities in the market, thereby supplementing the market growth.

Restraints/Challenges

• Lack of Awareness

Lack of awareness associated with using anti-hypertensive drugs among the population is one of the leading restraints in the global hypertension market. People are often ignorant about their health check-ups, particularly in developing nations, and aren't aware of the prevailing high blood pressure situation until they come across severe signs and symptoms.

• Irregularity in Medicine Consumption

People diagnosed with high blood pressure don't stick to their medicinal drug timetable and stop taking medicine after 1-2 weeks until signs and symptoms return, thus posing a large challenge to the global hypertension market. For instance, BMC Research performed a survey that states that out of the overall 112 hypertensive subjects with stroke, most effective 17% of them had been adherent to antihypertensive medications. Lack of awareness and low adherence to the drugs can limit the growth of the global hypertension market.

This global hypertension market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hypertension market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In December 2021, Dr. Reddy's Laboratories launched Valsartan tablets in the United States for the treatment of high blood pressure and heart collapse. The U.S. Food and Drug Administration (USFDA) has approved Diovan's generic therapeutic substitute

Global Hypertension Market Scope

The global hypertension market is segmented on the basis of type, treatment, measurement categories, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Primary Hypertension
• Secondary Hypertension
• Others

Treatment

• Medication
• Additional Therapy
• Others

Measurement Categories

• Normal Blood Pressure
• Elevated Blood Pressure
• Stage 1 Hypertension
• Stage 2 Hypertension
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Hypertension Market Analysis/Insights

The global hypertension market is analysed and market size insights and trends are provided by country, type, treatment, measurement categories, end-user and distribution channel as referenced above.

The countries covered in the global hypertension market  report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Asia-Pacific dominates the global hypertension market to grow during the forecast period due to the increased prevalence of hypertension diseases and the increasing geriatric population in the region.   

North America has been witnessing positive growth in the global hypertension market due to the increased R&D activities in the industry and higher healthcare expenditure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The global hypertension market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global hypertension market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global hypertension market. The data is available for historic period 2015-2021.

Competitive Landscape and Global Hypertension Market Share Analysis

全球高血压市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球高血压市场的关注有关。

全球高血压市场的一些主要参与者包括：

• F. Hoffmann-La Roche Ltd（瑞士）
• 费森尤斯卡比公司（德国）
• 拜耳公司（德国）
• 太阳制药工业有限公司 (印度)
• 诺华公司（瑞士）
• Mylan NV（美国）
• 梯瓦制药工业有限公司 (以色列)
• Zydus 集团 (印度)
• 辉瑞公司（美国）
• 鲁冰花（印度）
• 葛兰素史克公司（英国）
• Glenmark Pharmaceuticals Inc.（印度）
• Wockhardt（印度）

SKU-55509